AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03861611
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
Trial: NCT03861611
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
Trial: NCT01653483
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel Dry-Powder Inhaler
Trial: NCT01653483
Drug: GSK573719matched-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel Dry-Powder Inhaler
Trial: NCT01017029
Drug: Mycophenolate mofetil + Everolimus
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01394718
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
Trial: NCT04156191
Drug: ARQ-151 cream 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
Trial: NCT04156191
Drug: ARQ-151 cream 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
Trial: NCT00704912
Drug: Loestrin 1/20
RxNorm normalized name: Loestrin 1/20 21 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be started on a low dose containing OCP for a continuous 4 month period.
Trial: NCT00096954
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
Trial: NCT04505514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding
Trial: NCT01671384
Drug: Valproate, Levocarnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Trial: NCT01671384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Trial: NCT01702350
Drug: GSK2251052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of an an antibacterial
Trial: NCT02323659
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 20mg per dose, administered orally, once every week
Trial: NCT03197584
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03197584
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03197584
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT03197584
Drug: omega-3 acid ethyl esters
RxNorm normalized name: omega-3 acid ethyl esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 acid ethyl esters
Trial: NCT01456052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally.
Trial: NCT01779947
Drug: Estradiol Vaginal Tablets 10 mcg
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01779947
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03791827
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
Trial: NCT03791827
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
Trial: NCT03791827
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The recommended dose of azathioprine is 1.5 to 2mg/kg/d
Trial: NCT00964132
Drug: NRX194204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once Daily, Oral
Trial: NCT00443612
Drug: Irbesartan/Hydrochlorothiazide
RxNorm normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
Trial: NCT00381251
Drug: Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01037322
Drug: placebo in drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olive oil containing no drug given in drops twice daily
Trial: NCT01442038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Trial: NCT00543491
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02746068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00190866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00087191
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00182871
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00791310
Drug: Flucis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG injected i.v
Trial: NCT00460473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00143117
Drug: UK-390,957
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00263081
Drug: Current lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
Trial: NCT00982124
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
Trial: NCT00721266
Drug: RO5083945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
Trial: NCT01113710
Drug: Neupro®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neupro® is the exposure/intervention of interest in this non-interventional study.
Trial: NCT02542384
Drug: CR845 IV 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Trial: NCT02175784
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00739050
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20mg daily at nights for 12 weeks. Tablets
Trial: NCT01710852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00739050
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily at nights for 12 weeks. Tablets
Trial: NCT00884533
Drug: Rosi XR
RxNorm normalized name: Zinc Oxide 20 g in 100 mL TOPICAL LOTION [Stem Cellular CC Cream rosy glow]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosi XR
Trial: NCT03336632
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/Kg intravenously D+3, +4
Trial: NCT03989115
Drug: RMC-4630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-4630 for oral administration
Trial: NCT01563471
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Trial: NCT02947061
Drug: Capecitabine plus Docetaxel
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
Trial: NCT01042977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Trial: NCT00488072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet by mouth daily.
Trial: NCT03833167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion on Day 1 of each 42-day cycle
Trial: NCT02594241
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Trial: NCT01822678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01905410
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water for injection
Trial: NCT02034071
Drug: DCCR
RxNorm normalized name: Diazoxide Choline Controlled-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02034071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00200551
Drug: Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00200551
Drug: Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01291433
Drug: Clodronate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
Trial: NCT04108377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic look of Roflumilast capsule
Trial: NCT04148833
Drug: LDE-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
Trial: NCT03799172
Drug: Echinocandin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
Trial: NCT03799172
Drug: Triazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida.
Trial: NCT00225043
Drug: Epinephrine/phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03467412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injection
Trial: NCT00049634
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00049634
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01082731
Drug: Artemether-Lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
Trial: NCT04670757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00006129
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04315935
Drug: Fentanyl and Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
Trial: NCT00337350
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo for rosiglitazone 4mg/day
Trial: NCT00014404
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01967758
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
Trial: NCT01164540
Drug: Rosuvastatin (AZD4522)
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral dose (od) 20 mg
Trial: NCT01164540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose (od)
Trial: NCT03588299
Drug: BAY2599023 (DTX201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
Trial: NCT03335020
Drug: Contrast-Enhanced Ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
Trial: NCT03176758
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
Trial: NCT04639466
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM in the non-dominant upper arm
Trial: NCT03729973
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes.
Trial: NCT03155997
Drug: Standard Adjuvant Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to label instructions.
Trial: NCT00976170
Drug: GC33(RO5137382)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration at 6 escalating dose levels.
Trial: NCT03862716
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose is titrated to achieve fasting normoglycemia
Trial: NCT01859325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00727831
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00727831
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03858231
Drug: Norco 5Mg-325Mg Tablet
RxNorm normalized name: Norco 5mg-325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet up to 4 times per day for 7 days
Trial: NCT03858231
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet up to 4 times per day for 7 days
Trial: NCT03858231
Drug: Acetaminophen 325Mg Tab
RxNorm normalized name: ACETAMINOPHEN 325MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet up to 4 times per day for 7 days
Trial: NCT06025851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT04440982
Drug: LUM015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Trial: NCT02356965
Drug: Placebo (for Ketamine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sugar pill developed to mimic ketamine sublingual dose.
Trial: NCT00062673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02927262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04121416
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction with 0.3 µg/kg of Sufentanil in general anesthesia
Trial: NCT03412071
Drug: Topical Clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see description under arms
Trial: NCT00586066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive comparator. Placebo-matching memantine tablet.
Trial: NCT03191240
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00208299
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg/min for 6 minutes, intravenous infusion
Trial: NCT02896868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT00986479
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of 150 mg AZD6765.
Trial: NCT00986479
Drug: Placebo to AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of Placebo to AZD6765
Trial: NCT00484718
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 100 mg bid